Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy (SPOTLIGHT)

NCT04186845 is registered in ClinicalTrials.gov with Blue Earth Diagnostics as lead sponsor.

NCT NCT04186845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04186845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy (SPOTLIGHT)
Lead sponsor
Blue Earth Diagnostics
Phase
Phase 3
Overall status
Completed
Start date
May 4, 2020
Completion date
April 28, 2021
Enrollment
391 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer